Vania Modesto-Lowe, MD, MPH

Hartford Behavioral Health, Hartford, Connecticut, University of Connecticut Community Faculty, Farmington, Connecticut

JCP
Opioid Use Disorder in Sexually and Gender Diverse Populations: Can We Do Better?
Letter to the Editor

February 3, 2025

The authors respond to a recent JCP article by McDowell and colleagues.
, ,
JCP
Detecting Misuse of Prescription Opioids
Letter to the Editor

October 21, 2024

The authors discuss the difficulty in screening for opioid misuse and the need for clinicians to gain confidence in initiating difficult discussions with patients on long-term opioid treatment.
, ,
PCC
Harm Reduction in Adolescent Inhalant Use
Letter to the Editor

October 15, 2024

The authors discuss harm reduction efforts targeting inhalant use in the adolescent population.
, ,
PCC
Smartphone Applications: Therapy at Your Fingertips
Letter to the Editor

August 20, 2024

Dr Modesto-Lowe and colleagues discuss the advancements in smartphone applications for psychiatry, as well as some of the risks.
, ,
PCC
Zeroing in on Xylazine
Letter to the Editor

August 15, 2024

Dr Kaur and colleagues discuss the need to raise awareness among US public and health care professionals about xylazine due to its infiltration into the illicit drug supply.
, ,
PCC
Fentanyl Test Strips and Drug Use Modification
Letter to the Editor

May 14, 2024

The authors explore the use of fentanyl test strips as a harm reduction tactic to identify contaminated substances for people who use illicit drugs.
, ,
PCC
Do Not Overlook Bupropion Misuse
Letter to the Editor

April 30, 2024

Jasleen Kaur, MD, and colleagues comment on a case report published in the PCC.
, ,
PCC
Deprescribing Benzodiazepines: Is Harm Reduction Enough?
Letter to the Editor

December 28, 2023

Vania Modesto-Lowe, MD, MPH, and Claire N. Aurilio, BS, comment on a recent publication in the PCC.
,
PCC
Social Determinants of Health and Extended-Release Naltrexone
Brief Report

June 29, 2023

Patients with alcohol use disorder are at high risk of treatment nonadherence and readmission. While ER naltrexone can help prevent relapse for 28 days, they may face homelessness for...
,
PCC
Buprenorphine Maintenance in the Fentanyl Era
Letter to the Editor

February 14, 2023

Methods to foster patient adherence and physician acceptability of buprenorphine maintenance are needed to incorporate this treatment into primary care for fentanyl users.
,
PCC
Mindfulness Training in Opioid Withdrawal
Letter to the Editor

June 30, 2022

In this letter to the editor, the authors comment on an article published recently in the PCC.
, ,
PCC
The Hidden Curriculum in Addiction Training
Letter to the Editor

March 24, 2022

In this letter to the editor, the authors discuss the stigma associated with addiction treatment, as well as strategies to increase addiction literacy among physicians.
,

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe